PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsEpoetin
Epogen/procrit, Neorecormon(epoetin alfa)
Abseamed, Binocrit, Epoetin Alfa, Epogen/Procrit, Procrit, Retacrit (epoetin alfa) is a protein pharmaceutical. Epoetin alfa was first approved as Epogen/procrit on . It is used to treat anemia in the USA. It has been approved in Europe to treat anemia, chronic kidney failure, and neoplasms. It is known to target erythropoietin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Epogen/procrit, Retacrit
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Epoetin alfa
Tradename
Proper name
Company
Number
Date
Products
Epogen/Procritepoetin alfaAmgenN-103234 RX
5 products
Procritepoetin alfaAmgenN-103234 RX
1 products
Epogen/Procritepoetin alfaAmgenN-103234 RX1989-06-01
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
epochOTC monograph not final2022-01-12
epoch ava puhi moni anti-dandruffC2002632024-12-31
epogenBiologic Licensing Application2025-04-14
nu skin epochOTC monograph final2009-12-14
procritBiologic Licensing Application2025-04-09
retacritBiologic Licensing Application2024-06-26
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
epoetin alfa, Epogen/Procrit, Amgen, Inc.
1997-12-31Orphan excl.
epoetin alfa, Procrit, Amgen, Inc.
1997-12-31Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code
Description
J0881
Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J0882
Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis)
J0885
Injection, epoetin alfa, (for non-esrd use), 1000 units
Q4081
Injection, epoetin alfa, 100 units (for esrd on dialysis)
Q5105
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
Q5106
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
Clinical
Clinical Trials
879 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnemiaD000740EFO_0004272D64.9443212
Kidney diseasesD007674EFO_0003086N08516
Chronic renal insufficiencyD051436N18426
Chronic kidney failureD007676EFO_0003884N18.6112
Renal insufficiencyD051437N1922
Colorectal neoplasmsD01517911
Renal dialysisD006435EFO_0010690Z99.211
Erythrocyte transfusionD01770711
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80134
LymphomaD008223C85.922
Hematologic neoplasmsD019337111
Prostatic neoplasmsD011471C61111
Large b-cell lymphoma diffuseD016403C83.311
LeukemiaD007938C9511
Multiple myelomaD009101C90.011
Precancerous conditionsD01123011
Lymphoproliferative disordersD008232Orphanet_2442D47.911
Plasma cell neoplasmsD05421911
Show 1 more
Indications Phases 2
Indications Phases 1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CytopeniaD00009554299
PancytopeniaD010198D61.8188
Diabetic retinopathyD003930EFO_000377033
Iron metabolism disordersD019189E83.122
Hemolytic anemiaD000743D55-D5922
Surgical blood lossD01606322
Respiratory insufficiencyD012131J96.922
FibrosisD00535522
Type 1 diabetes mellitusD003922EFO_0001359E1022
Coronary artery bypassD001026EFO_000377622
Show 58 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEpoetin alfa
INNepoetin alfa
Description
Erythropoietin precursor (Epoetin)
Classification
Protein
Drug classerythropoietins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL1201565
ChEBI ID
PubChem CID
DrugBankDB00016
UNII ID64FS3BFH5W (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
EPOR
EPOR
Organism
Homo sapiens
Gene name
EPOR
Gene synonyms
NCBI Gene ID
Protein name
erythropoietin receptor
Protein synonyms
Uniprot ID
Mouse ortholog
Epor (13857)
erythropoietin receptor (Q63852)
Variants
No data
Financial
Revenue by drug
$
£
Epogen Amgen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Procrit Johnson & Johnson
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Retacrit Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Epoetin alfa
+
Epoetin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 90,537 documents
View more details
Safety
Black-box Warning
Black-box warning for: Epogen, Procrit, Retacrit
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
60,879 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use